Skip to main content
Company record · Anderlecht
Belgian companySituation normaleSociété coopérative

Multipharma

Enterprise number
0866.855.346
VAT number
BE0866855346
Registered office
Square Marie Curie 30, 1070 Anderlecht
See the 15 companies at this address
Incorporated on
19 August 2004
Members only
Health score
Latest financial year
2025
m82-f model
Size
Large
1.522,8 FTE
Equity
€128.1M
Financial year 2025
Net result
-€2.9M
Financial year 2025

Profile

Official information from the CBE (FPS Economy).

Multipharma is a Belgian company (Société coopérative) whose registered office is established at 1070 Anderlecht. Its main activity falls under “Autre commerce de détail non spécialisé” (NACE 47120).

Legal form
Société coopérative
Legal situation
Situation normale
Date of incorporation
19 August 2004
Main activity (NACE)
47120Autre commerce de détail non spécialisé

An activity that is, on the face of it, not covered by anti-money-laundering law. Learn more

Your risk analysis on this company

AML Company ran Multipharma through your due diligence questionnaire. Here are the first findings.

  • What is the geographic exposure of the client and of its transactions?

    Belgium only· Registered office published in the register

  • What is the company's solvency and lifecycle status?

    Trading, no proceedings· Legal situation published in the register

The rest of the analysis

Sanctions screening, politically exposed persons, ultimate beneficial owners, source of funds: AML Company runs them, documents them and keeps the proof in your file.

Run the full analysis

Log in

This preview is not a due diligence measure: it pre-qualifies questions from public data. Identifying the client and its ultimate beneficial owners requires documents collected and verified.

Establishments

244 active establishment units declared with the CBE.

2732
Implantation
Anderlecht

30 establishments · 20 municipalities

Registered office30 establishments
Registered office
Square Marie Curie 30
Map
Establishment2142.555.596
Rue de Bois-de-Breux 282
4020 Liège
Map
Establishment 22224.224.549
Rue de la Station(Wal) 42
Map
Establishment 32224.225.044
Rue Xavier De Bue 31
1180 Uccle
Map
Establishment 42240.114.040
Pastorijstraat 1
Map
Establishment 52264.570.512
Rue Vanderkindere 190
1180 Uccle
Map

30 shown out of 244 active establishments

Finances & financial health

Annual accounts filed with the Central Balance Sheet Office (CBSO, National Bank of Belgium) and an aggregate health score (Altman Z″ model, completed with qualitative factors).

Zone Altman
Grade
Computed on
Financial trend

Equity & result

EquityResult
Key figures by financial year
Financial yearEquityResult
2025€128,100,759-€2,856,720
2022€95,973,899€5,033,516
2021€90,439,475€7,197,775
2020––

Financial ratios

Solvency, liquidity and profitability, computed year by year from the filed annual accounts.

Solvency
46,7%
3,1%
Financial year 2025

Equity / balance sheet total

Liquidity
1,62 x
0,08
Financial year 2025

Current assets / debts due within one year

Net margin
-0,5%
1,5%
Financial year 2025

Result for the year / turnover

Operating margin
-0%
2%
Financial year 2025

Operating result / turnover

Long-term debt
18,1%
6,6%
Financial year 2025

Debts due after one year / balance sheet total

Return on equity
-2,2%
7,5%
Financial year 2025

Result for the year / equity

Over the most recent filed years

Balance sheet structure

SolvencyLong-term debt
Year-on-year comparison
Ratio202520222021Trend
Solvency
46,7%
3,1%
49,8%
1,6%
48,2%
Liquidity
1,62 x
0,08
1,7 x
0,08
1,62 x
Net margin
-0,5%
1,5%
1%
0,5%
1,5%
Operating margin
-0%
2%
2%
0,5%
2,5%
Long-term debt
18,1%
6,6%
11,5%
1,6%
13,1%
Return on equity
-2,2%
7,5%
5,2%
2,7%
8%

Ratios computed by AML Company from the items filed in the balance sheet and the income statement. They are not filed figures as such: the underlying amounts appear in the key figures above.

Filing history (9)▾
Financial yearFilingFiling typeModelSource
01/01/2025 → 31/12/202514/10/2026Correctionm82-fBNB
01/01/2025 → 31/12/202525/06/2026Initialm82-fBNB
01/01/2022 → 31/12/202202/08/2023Initialm82-fBNB
01/01/2021 → 31/12/202122/06/2022Initialm82-fBNB
01/01/2020 → 31/12/202011/08/2021Initialm82-fBNB
01/01/2019 → 31/12/201927/10/2020Correctionm02-fBNB
01/01/2019 → 31/12/201902/07/2020Initialm02-fBNB
01/01/2018 → 31/12/201827/08/2019Correctionm02-fBNB
01/01/2018 → 31/12/201827/06/2019Initialm02-fBNB

Source: CBSO (NBB) filings, Belgian chart-of-accounts headings 9904 (result), 10/15 (equity), 9900 (gross margin), 9087 (workforce in FTE). Data available for filings from 2022 onwards.

Health score and detailed factors

The grade, the score out of 100, the Altman Z″ zone and the list of public alerts are for members only.

Unlock

Notices in the Belgian Official Gazette

Official acts and notices: incorporation, changes to the articles, appointments, dissolutions.

Source: Belgian Official Gazette (FPS Justice). The links open the official PDFs.

What the Multipharma record does not say

Two readings of the register the raw data does not give: anti-money-laundering scope, and whether the filing deadline was met.

Is Multipharma subject to anti-money-laundering obligations in Belgium?
In principle no. The activity declared in the register for Multipharma is not among the professions expressly covered by the act of 18 September 2017. This general information is not legal advice.
Did Multipharma file its annual accounts on time?
No. Multipharma filed its latest annual accounts with the Central Balance Sheet Office (CBSO, National Bank of Belgium) on 14 October 2026, 75 days after 31 July 2026. Article 3:10 of the Code of Companies and Associations requires filing at the latest seven months after the financial year closes. A late filing is a signal to document before entering a business relationship.

Company timeline

Every dated event in the company's life, from filed accounts to notices published in the Belgian Official Gazette, in a single thread.

Timeline
62 events
Filter the timeline by event type

10 AI-analysed dimensions are not shown.

  1. 2026
    1. 14 October 2026Annual accounts filed·Financial year ended 31 December 2025 · Model m82-fFiled accounts2026-00559826
    2. 25 June 2026Annual accounts filed·Financial year ended 31 December 2025 · Model m82-fFiled accounts2026-00205852
    3. 23 June 2026Appointments · ResignationsView the notice26079797
  2. 2025
    1. 21 October 2025RestructuringView the notice25133010
    2. 26 August 2025Restructuring · MiscellaneousView the notice25108127
    3. 3 July 2025Appointments · ResignationsView the notice25082618
    4. 24 June 2025Capital · Shares · Appointments · Resignations · RestructuringView the notice25078798
    5. 11 April 2025Restructuring · MiscellaneousView the notice25047724
    6. 14 February 2025Appointments · ResignationsView the notice25023094
  3. 2024
    1. 26 November 2024Appointments · ResignationsView the notice24167057
    2. 17 July 2024Appointments · ResignationsView the notice24107520
    3. 11 July 2024RestructuringView the notice24104692

Registry record since 7 September 2026

The KBO publishes its changes as a monthly delta and never restates the past: our record starts on that date, not at the company's incorporation. No change recorded since that date. A missing row says nothing about the company, only about how far back our record goes.

AI insights · Pro AI plan

AI extraction of strategic AML data

The official notices in the Belgian Official Gazette are analysed by our AI engine to extract automatically the information that matters for your due diligence and your AML duties.

  • Legal life
  • Restructuring
  • Capital
  • Legal form
  • Incorporation
  • Directors
  • Beneficial owners
  • Registered office
  • Company name
  • Notarial deeds
AML Company

Step it up
Full analysis unlocked.

Create an account to unlock the detailed analysis: health score, full history, alerts and PDF exports.

    We respect your privacy

    We use cookies that are essential to running the site and, with your consent, audience-measurement cookies (hosted in the EU) to improve our services. Learn more.